Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan A Lafferty

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Frontiers in Endocrinology|May 31, 2021
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-DiabetesNeil Tanday, Andrew English, Ryan A Lafferty, et al.
Biofactors (Oxford, England)|April 18, 2024
Novel enzyme-resistant pancreatic polypeptide analogs evoke pancreatic beta-cell rest, enhance islet cell turnover, and inhibit food intake in miceWuyun Zhu, Neil Tanday, Ryan A Lafferty, et al.
Peptides|February 24, 2022
Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineageShruti Mohan, Ryan A Lafferty, Peter R Flatt, et al.
Biochemical Pharmacology|December 29, 2022
Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed miceAndrew G McCloskey, Michael G Miskelly, Ryan A Lafferty, et al.
Frontiers in Endocrinology|June 7, 2021
Proglucagon-Derived Peptides as TherapeuticsRyan A Lafferty, Finbarr P M O'Harte, Nigel Irwin, et al.
The Journal of Pharmacy and Pharmacology|October 7, 2022
Effects of artemether on pancreatic islet morphology, islet cell turnover and α-cell transdifferentiation in insulin-deficient GluCreERT2;ROSA26-eYFP diabetic miceDipak Sarnobat, Ryan A Lafferty, R Charlotte Moffett, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Peptide YY (1-36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β-cell function, growth and survivalRyan A Lafferty, Neil Tanday, Andrew McCloskey, et al.
The Journal of Endocrinology|August 25, 2022
Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed miceRyan A Lafferty, Laura M McShane, Zara J Franklin, et al.
Frontiers in Endocrinology|March 15, 2021
Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic MiceRyan A Lafferty, Neil Tanday, R Charlotte Moffett, et al.
Biochimie|April 19, 2022
Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed miceZara J Franklin, Ryan A Lafferty, Peter R Flatt, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Endocrinology|May 31, 2021
Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-DiabetesNeil Tanday, Andrew English, Ryan A Lafferty, et al.
Biofactors (Oxford, England)|April 18, 2024
Novel enzyme-resistant pancreatic polypeptide analogs evoke pancreatic beta-cell rest, enhance islet cell turnover, and inhibit food intake in miceWuyun Zhu, Neil Tanday, Ryan A Lafferty, et al.
Peptides|February 24, 2022
Ac3IV, a V1a and V1b receptor selective vasopressin analogue, protects against hydrocortisone-induced changes in pancreatic islet cell lineageShruti Mohan, Ryan A Lafferty, Peter R Flatt, et al.
Biochemical Pharmacology|December 29, 2022
Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed miceAndrew G McCloskey, Michael G Miskelly, Ryan A Lafferty, et al.
Frontiers in Endocrinology|June 7, 2021
Proglucagon-Derived Peptides as TherapeuticsRyan A Lafferty, Finbarr P M O'Harte, Nigel Irwin, et al.
The Journal of Pharmacy and Pharmacology|October 7, 2022
Effects of artemether on pancreatic islet morphology, islet cell turnover and α-cell transdifferentiation in insulin-deficient GluCreERT2;ROSA26-eYFP diabetic miceDipak Sarnobat, Ryan A Lafferty, R Charlotte Moffett, et al.
Diabetes, Obesity & Metabolism|November 7, 2019
Peptide YY (1-36) peptides from phylogenetically ancient fish targeting mammalian neuropeptide Y1 receptors demonstrate potent effects on pancreatic β-cell function, growth and survivalRyan A Lafferty, Neil Tanday, Andrew McCloskey, et al.
The Journal of Endocrinology|August 25, 2022
Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed miceRyan A Lafferty, Laura M McShane, Zara J Franklin, et al.
Frontiers in Endocrinology|March 15, 2021
Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic MiceRyan A Lafferty, Neil Tanday, R Charlotte Moffett, et al.
Biochimie|April 19, 2022
Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed miceZara J Franklin, Ryan A Lafferty, Peter R Flatt, et al.
Pageof 3